Related Topics:
Facility ID: 01845PHRMC70FLA
Facility Name and Address: VERANOVA L.P. 70 FLAGSHIP DR NORTH ANDOVER, MA 01845 Parent Company: AHP-VERANOVA LP Industry: Pharmaceutical Preparation Manufacturing (325412) Chemical: Methanol Reports: View TRI Facility profile report for this facility View TRI Form R submissions by this facility |
|
*You can navigate within the map with your mouse. |
Production Related Waste Management for Selected Chemical
lchemid=0000067561
Chart Options1: |
Waste Management Comparison -
Display facility comparison report for this industry and chemical
Display facility comparison report for this parent company
Pollution Prevention Activities for Selected Chemical
Reporting Year | Section 8.10: Newly Implemented Source Reduction Activity | Section 8.10: Methods to Identify Activity | Section 8.11: Optional Pollution Prevention Information* |
---|---|---|---|
2019 |
Source Reduction:: W71: Other cleaning and degreasing modifications
|
Methods to Identify SR Opportunities: T11: Other
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction. |
W71: When possible, methanol will be reused for cleaning processes within campaigns. This may be permitted by the client and when acceptable this can reduce the use of methanol by 1 drum per client's batch. Source Reduction - Reusing solvents for repeat cleanings was offered by production coordinators and project managers must receive approval from client representatives before proceeding. Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - JM IS A CONTRACT PHARMACEUTICAL MANUFACTURING AND RESEARCH FIRM WHICH MANUFACTURES PRODUCTS ON A BATCH BASISBY CLIENT. THE CLIENTS PROJECTS DICTATE THE CHEMICALS USED AND THE QUANTITIES. AS THESE PRODUCTS MAY BE IN FDAAPPROVAL PROCESS OR ALREADY FDA APPROVED JM HAS LITTLE OPPORTUNITY TO ENCOURAGE LESS HAZARDOUS CHEMICALSUBSTITUTIONS. WHEN POSSIBLE IN EARLY STAGES OF WORKING WITH NEW CLIENT, JM WILL OPTIMIZE PROCESSES WHICH MAYRESULT IN LESS CHEMICALS USED OVERALL BY REDUCING NUMBER OF FILTRATIONS, WASHES, ETC. CHEMICALS USED AND VOLUMESUSED WILL VARY YEAR BASED ON CLIENTS' PROJECTS AND SPECIFICATIONS. 2019 PROJECTS REQUIRED DECREASED USE OF METHANOL. |
2018 |
Source Reduction:: W71: Other cleaning and degreasing modifications[-0-4%]
|
Methods to Identify SR Opportunities: T05: Employee recommendation (independent of a formal company program)
|
W71: When possible, methanol will be reused for cleaning processes within campaigns. This may be permitted by the client and when acceptable this can reduce the use of methanol by 1 drum per client's batch. Source Reduction - Reusing solvents for repeat cleanings was offered by production coordinators and project managers must receive approval from client representatives before proceeding. |
2017 |
Other Environmental Practices - JM IS A CONTRACT PHARMACEUTICAL MANUFACTURING AND RESEARCH FIRM WHICH MANUFACTURES PRODUCTS ON A BATCH BASIS BY CLIENT. THE CLIENTS PROJECTS DICTATE THE CHEMICALS USED AND THE QUANTITIES. AS THESE PRODUCTS MAY BE IN FDA APPROVAL PROCESS OR ALREADY FDA APPROVED JM HAS LITTLE OPPORTUNITY TO ENCOURAGE LESS HAZARDOUS CHEMICAL SUBSTITUTIONS. WHEN POSSIBLE IN EARLY STAGES OF WORKING WITH NEW CLIENT, JM WILL OPTIMIZE PROCESSES WHICH MAY RESULT IN LESS CHEMICALS USED OVERALL BY REDUCING NUMBER OF FILTRATIONS, WASHES, ETC.
Other Environmental Practices: Energy Recovery - JM approved waste disposal facilities seek energy recovery disposal options whenever possible. |
||
2016 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
|
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - Active pharmaceutical ingredients and intermediates are made using the development methods and materials required by the clients. If an API is going through clinical trials or development, clients will not allow chemical substitutions due to concerns regarding any FDA submittals that have been processed or are being processed. Chemical changes may affect the FDA submittal and can result in FDA rejection of a phase 1, 2 or 3 submittal. |
|
2015 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
|
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - Active pharmaceutical ingredients and intermediates are made using the development methods and materials required by the clients. If an API is going through clinical trials or development, clients will not allow chemical substitutions due to concerns regarding any FDA submittals that have been processed or are being processed. Chemical changes may affect the FDA submittal and can result in FDA rejection of a phase 1, 2 or 3 submittal. |
|
2014 |
Other Barriers to Source Reduction - The batch process production schedule and the clients needs determine which chemicals are used during the year. If the client's product is part of an FDA approved process no chemical substitiutions are permitted. This limits process changes and reduces opportunity for source reduction. |
||
2013 |
Source Reduction:: W56: Reduced or eliminated use of an organic solvent
|
Methods to Identify SR Opportunities: T11: Other
|
Source Reduction - The operations team discusses if there are processes which would allow for reuse of solvents. Source Reduction - When possible solvents used for distillation may be used for an additional cleaning process rather than use virgin solvent. The ability to reuse solvents is dictated by the process and the client. |
2012 |
Other Barriers to Source Reduction - The particular chemistry performed by the site in the production of client specific compounds requires use of certain solvents. Efforts are made to substitute less hazardous chemicals when possible but this is not feasible in most circumstances. |